Glenmark Becomes First Pharmaceutical Company to Launch Fixed-Dose Combination Drug Teneligliptin + Pioglitazone for Type 2 Diabetes in India

The innovative fixed-dose combination will help improve glycemic control in adult patients with insulin resistance, those whose diabetes is not controlled on metformin; and also those that require the addition of Teneliglitptin and Pioglitazone as separate drugs.

Launched under the brand name Zita Plus Pio, the drug will increase the accessibility of quality medicines for effective diabetes management.

Zita Plus Pio is the only DPP4 and Glitazone combination brand available in India.

Mumbai, India, April 25, 2022 /PRNewswire/ — Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company, has launched a new fixed-dose combination (FDC) of a widely used DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor), the teneligliptin, with pioglitazone. This is the only DPP4 and Glitazone combination brand available in India for adults with uncontrolled type 2 diabetes. Glenmark launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20mg) + Pioglitazone (15mg), to be taken once daily.

Commenting on the development, Alok MalikGroup Vice President & Head, India Formulations – Glenmark Pharmaceuticals, said: “Diabetes is a key focus area for Glenmark; a pioneer in providing access to the latest treatment options for diabetes patients in India. We are delighted to present this novel to you. Zita Plus Piowhich is the first of its kind in India; providing a world-class, affordable treatment option for adult patients with diabetes. »

Glenmark is the first company to India to market the innovative FDC of Teneligliptin + Pioglitazone, approved by the DCGI (General Controller of Medicines India). This fixed dose combination will be useful for patients who require treatment with teneliglittin and pioglitazone (as separate drugs) to improve glycemic control by reducing insulin resistance.

Type 2 diabetics typically face problems with β-cell dysfunction and insulin resistance. Glenmark’s FDC of Teneligliptin + Pioglitazone has the efficacy to address these two most important pathophysiologies, making FDC most effective in the management of uncontrolled type 2 diabetes. The combination of Teneligliptin + Pioglitazone will provide a synergistic approach in which Teneligliptin will optimally improve β-cell sensitivity, and Pioglitazone will effectively reduce insulin resistance.

Glenmark’s contribution to the treatment of diabetes

In 2015, Glenmark revolutionized the diabetes market by launching its DPP4 inhibitor – Teneligliptin in India, followed by a FDC of Teneligliptin + Metformin. Glenmark has a strong heritage of over four decades of progress and innovation. In continuity with his first time in India legacy, he launched FDC of Teneligliptin + Remogliflozin in 2021.

India is known to be the diabetes capital of the world. According to the International Diabetes Federation (IDF), the prevalence of diabetes in India is about 74 million adults, which is expected to increase to 125 million (nearly 70% increase) by 2045[i]. Of these, 77% of patients have uncontrolled diabetes[ii].

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with operations in the specialty, generic and over-the-counter sectors. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing plants across 4 continents and operations in over 80 countries. Glenmark is ranked among the top 100 biopharmaceutical companies in the world (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the top 50 global companies in the non-patent sector (Top 50 Generics and Biosimilars Companies ranking by Sales, 2020, by Generics Bulletin/In Vivo). The company has been listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, in the Emerging Markets category (2021) for the fourth consecutive year . For more information, visit www.glenmarkpharma.com

Reference:

[i] Diabetes research and clinical practice. 2022 January 1st;183:109119.

[ii] BMJ Open Diabetes Research and Care. 2019 1 Jul;7(1):e000654.

For more information please contact:
Udaykumar Murthy
Deputy Managing Director, Corporate Communications
+91 9960377617 | [email protected]

Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg

SOURCEGlenmark Pharmaceuticals Ltd

Comments are closed.